Conditions of your grant
These grant conditions, together with the grant award letter and the funding policies, set out the terms and conditions on which we make a grant to the host institution and grant holder.
Table of contents
(together, the Terms and Conditions).
The Terms and Conditions may be amended at any time by HMF and apply to the Grant as amended. To the extent of any inconsistency between the Grant Conditions and the GAL, the GAL prevails.
HMF also reserves the right for it, or its agents, to investigate any aspect of fraud or misconduct itself and the Host Institution and Grant holder shall provide assistance and information to HMF for that purpose.
|ARRIVE Guidelines||Animal Research: Reporting of In Vivo Experiments Guidelines published by the UK National Centre for the Replacement, Refinement & Reduction of Animals in Research.|
|Centre||The network of cancer-research activity supported by grants described as HMF centres grants.|
|Clinical Practice Standards||Guidance relating to medicines and clinical trials in force in the jurisdiction in which that Team Member is carrying out Activities or is registered, including the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and the World Medical Association Declaration of Helsinki entitled ‘Ethical Principles for Medical Research Involving Human Subjects’ (2008 version), in each case, as amended from time to time. For the avoidance of doubt, in the UK this includes the MRC Guidelines for Good Clinical Practice.|
|HMF||Human Milk Foundation, a registered charity in England and Wales (1172522), and a company limited by guarantee registered in England & Wales No. CE010017 and whose registered address is Troll House, Church Road, Ham, Richmond, TW10 5HG.|
|Directly Allocated Costs||Costs of resources used by a project that are shared by other activities and based on estimates rather than actual costs (e.g. principal and co-investigator costs, estates costs).|
|Direct Costs||The costs explicitly identifiable as arising from the conduct of a project. In determining whether a cost is a Direct Cost, the Host Institution must follow any Costs Guidance issued by HMF from time to time.|
|ECMC||Experimental Cancer Medicine Centre.|
|End Date||The date that is the number of months from the Start Date that is equivalent to the duration of the award set out in the GAL, or such earlier date that the Grant is terminated.|
|Equipment||The equipment required to conduct the Grant Activities which costs £5,000 or more.|
|Funded Materials||Biological and chemical materials comprised in Funded Intellectual Property.|
|Funding Policies||The funding policy statements published on HMF’s website, as updated from time to time.|
|GAL||The grant award letter from HMF containing the details, and offer, of the Grant.|
|Grant||The funding made pursuant to and described in the GAL.|
|Grant Activities||The research and investigation funded by the Grant as described in the GAL.|
|Grant Conditions||The conditions set out in sections 1 to 16 of this document.|
|Grant Period||The period between the Start Date and End Date.|
|Grant holder||The lead applicant, any joint applicant as specified in the GAL and, for Institute Core Awards, HMF-funded group leaders.|
|Host Institution||The university, research institution, company or other entity at which some or all of the Grant Activities will be carried out, as named in the GAL.|
|Human Biological Samples||Tissue, blood and other biological samples taken from humans.|
|Institutions||Any university, research institution or other entity at which some or all of the Grant Activities will be carried out other than the Host Institution.|
|Indirect Costs||Non-specific costs charged across all projects that are based on estimates (eg. human resources, finance, library and departmental services).|
|NIHR CRN Portfolio||A database of the clinical research studies that are supported by the National Institute of Health Research Clinical Research Network in England.|
|P&I||HMF’s Policy & Information directorate.|
|Research Personnel||The Grant holder and any person working on the Grant Activities under his/her supervision, including (as applicable), any co-investigator or collaborator, sponsor, supervisor, consultant or sub-contractor.|
|Results||All inventions, discoveries, materials (including biological and chemical materials), technologies, products, data, algorithms, software, patents, databases, copyright, other intellectual property and know-how arising from Grant Activities.|
|Special Conditions||Any special conditions referred to in the GAL (or otherwise notified to the Grant holder and Host Institution) as applicable to the Grant in light of the nature of the funding scheme and Grant Activities.|
|Start Date||The date indicated in the GAL, or otherwise agreed with HMF, on which the Grant Activities commence.|
|Studentship||A Grant or part of a Grant pertaining to the funding of PhD students.|
|TTA||Technology Transfer Agreement being, unless HMF determines otherwise, a framework agreement governing the management and exploitation of Results as well as results of all other research funded by Cancer Research UK at the Host Institution from time to time.|
|Terms and Conditions||See definition in section 1.1.|
Schedule A. Conditions for host institutions with no technology transfer agreement with HMF
Schedule B. Conditions for policy and information targeted research projects
Should the Host Institution receive monetary or non-monetary income directly or indirectly from the commercial exploitation of Funded Intellectual Property, then the Host Institution shall share such income, in a reasonable proportion, with HMF.